AbbVie GK (Headquarters: Tokyo  President: James C Feliciano  "AbbVie") and Eisai Co  Ltd (Headquarters: Tokyo  CEO: Haruo Naito  "Eisai") announced today that they have received notification from Japan's Ministry of Health  Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of HUMIRA(R) Pre-filled Syringe 20 mg / 0